Update of a phase I/II trial of carboplatin/gemcitabine plus escalating doses of celecoxib for first-line treatment of stage IIIB/IV non-small cell lung cancer (NSCLC)

Burton, J. D.; Badine, Edgard; El-Sayah, D.; Dib, E.; Forte, Frank; Terjanian, Terenig; Odaimi, Marcel; Vesoniaraki, M.; Friscia, P.; Lowry, J.

doi:10.1200/jco.2004.22.14_suppl.7339

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Burton and colleagues conducted a phase I/II trial combining carboplatin (AUC 5 day 8) plus gemcitabine (1100 mg/m 2 days 1,8 every 21 days) with an escalating dose of celecoxib starting at 120 mg/m 2 and increasing to a maximum dose of 600 mg/m 2 (or ≍500 mg BID) days 1–12 39. Response was assessed every 2 cycles and those patients with stable disease or better were to receive up to 8 cycles of therapy.…”

Section: Introductionmentioning

confidence: 99%

Targeting the eicosanoid pathway in non-small-cell lung cancer

Horn

Backlund

Johnson

2009

Expert Opinion on Therapeutic Targets

View full text Add to dashboard Cite

Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early event in the development of non-small cell lung cancer. Preclinical data indicate tumors with upregulation of COX-2 synthesize high levels of prostaglandin E 2 (PGE 2 ) which in turn are associated with increased production of proangiogenic factors and enhanced metastatic potential. These findings suggest that an increase in COX-2 expression may play a significant role in the development and growth of lung cancers and possibly with the acquisition of an invasive and metastatic phenotype. Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers.

show abstract

Section: Introductionmentioning

confidence: 99%